Antineoplastic agents, and notably alkylating agents, have been associated with a potential risk of myelodysplastic syndrome (MDS) and secondary malignancies, including leukaemia.
Kasvajavastaste ainete ja eriti alküleerivate ainete kasutamisega kaasneb potentsiaalne müelodüsplastilise sündroomi (MDS) ja sekundaarsete maliigsuste, sh leukeemia oht.